You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers

Authors

Citation

Houacine J, Abes R, Marie-Cardine A, et al
1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1339

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.